Sie sind auf Seite 1von 16

Group No.

____
Section: ______
Members (indicate if absent)

Exercise Number: 1
Preparation of Red Cell Suspension
Objectives:
1.
2.
Procedure (In flowchart form)

Observation and Results:


Specimen Code: ________

2% RCS 5% RCS
Description: Description:

Show your Computations for the pRBC and NSS volume below
Computation Computation
Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 2
Serial Dilution
Objectives:
1.
2.
Procedure (In flowchart form) (Tube) Procedure (in flowchart form) (Microtiter Well)

Observation and Results:


Tube Method
Specimen Code: _____

Tube 1 Tube 2 Tube 3 Tube 4 Tube 5 Tube 6


NSS (ml)
Serum (ml) - - - - -
Transfer 0.5ml of Solution to Next Tube; Note: 0.5ml of the Mixture from Tube 6 is discarded
Serum
Dilution:
RCS Volume

Determine the Antibody Titer: _____________

Microtiter Well Method


Specimen Code: _____

Well 1 Well 2 Well 3 Well 4 Well 5 Well 6


NSS (ul)
Serum (ul) - - - - -
Transfer 50 ul of Solution to Next Well; Note: 50ul of the Mixture from Well 6 is discarded
Serum
Dilution:
RCS Volume

Determine the Antibody Titer: ____________

Group No. ____


Section: ______
Members (indicate if absent)

Exercise Number: 3
Agglutination
Objectives:
1.
2.
Procedure (In flowchart form)

Observation and Results:


Specimen Code: _____

Grade Description
From Tube 1

From Tube 2

From Tube 3

From Tube 4

From Tube 5

Tube 6
Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 4
Hemolysis and Complement Fixation
Objectives:
1.
2.
Procedure (In flowchart form)
Observation and Results:
Specimen Code: ________

Are Complement Fixing Antibodies Present in the Sample? ___________


Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 6
Serologic Tests for Syphilis
Objectives:
1.
2.
Procedure (In flowchart form)
• Immunologic Principle of TPHA: ___________________________

• Immunologic Principle of RPR: ____________________________

Observation and Results:


Specimen Code: ________
TPHA: Draw the appearance of the results obtained.

W1 W2 W3
Indicate the contents of the reagent in:
W2 : _____________
(+)C

W3 : _____________

Analyte of
(-)C

Interest:____________________________
• Interpretation:
________________________
• Clinical Significance:
Unk__

____________________

RPR

(+) Control (-) Control Unk: ___

RPR Reagent Contains:__________

Analyte of Interest: ____________


Describe the result obtained in (+) Control:___________
Describe the result obtained in (-) Control:___________
Describe the result obtained in Unk: ________________
Interpretation: ________________________

Clinical Significance: ____________________


Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 7
Serologic Tests: ASO Slide Test
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle Involved: ____________________________________

ASO Slide Test

(+) Control (-) Control Unk: ___

ASO Reagent Contains:__________


Analyte of Interest: ____________
Describe the result obtained in (+) Control:___________
Describe the result obtained in (-) Control:___________
Describe the result obtained in Unk: ________________

Detection Limit: ____________ IU/ml


Interpretation: ________________________
Clinical Significance:

Group No. ____


Section: ______
Members (indicate if absent)

Exercise Number: 8
Serologic Tests: CRP
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

CRP

(+) Control (-) Control Unk: ___

CRP Reagent Contains:__________


Analyte of Interest: ____________
Describe the result obtained in (+) Control:___________
Describe the result obtained in (-) Control:___________
Describe the result obtained in Unk: ________________

Detection Limit: ____________ mg/ml


Interpretation: ________________________
Clinical Significance:
Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 9
Serologic Tests: RF
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

RF

(+) Control (-) Control Unk: ___

RF Reagent Contains:__________
Analyte of Interest: ____________
Describe the result obtained in (+) Control:___________
Describe the result obtained in (-) Control:___________
Describe the result obtained in Unk: ________________

Detection Limit: ____________ IU/ml


Interpretation: ________________________
Clinical Significance:

Group No. ____


Section: ______
Members (indicate if absent)

Exercise Number: 10
Serologic Tests: SLE Test
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

SLE

(+) Control (-) Control Unk: ___

SLE Reagent Contains:__________


Analyte of Interest: ____________
Describe the result obtained in (+) Control:___________
Describe the result obtained in (-) Control:___________
Describe the result obtained in Unk: ________________

Interpretation: ________________________
Clinical Significance:
Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 11
Serologic Tests: IM Quick Test
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

CRP

(+) Control (-) Control Unk: ___

IM Reagent Contains:__________
Analyte of Interest: ____________
Describe the result obtained in (+) Control:___________
Describe the result obtained in (-) Control:___________
Describe the result obtained in Unk: ________________

Interpretation: ________________________
Clinical Significance:
Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 12
Serologic Tests: Bacterial Agglutination Test
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

Serum Approx. Rgt: Rgt: Rgt: Rgt: Rgt: Rgt: Rgt: Rgt:
Volume Tube
Dilution

0.08ml

0.04ml

0.02ml

0.01ml

0.005ml

Titer:

Analyte of Interest: _____________________

Interpretation: ________________________

Clinical Significance:
Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 12
Serologic Tests: HIV
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

Component/s fixed/embedded on the Control Line:


__________________________________________
Component/s fixed on the Test Line:
• 1: __________________________________________
• 2: __________________________________________

Interpretation:

__________________________________________
Clinical Significance:

Group No. ____


Section: ______
Members (indicate if absent)

Exercise Number: 13
Serologic Tests: S. typhi Test
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

Component/s fixed/embedded on the Control Line:


__________________________________________
Component/s fixed on the Test Line:
__________________________________________

Interpretation:

__________________________________________
Clinical Significance:
Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 14
Serologic Tests: Chikungunya Test
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

Component/s fixed/embedded on the Control Line:


__________________________________________
Component/s fixed on the Test Line:
__________________________________________

Interpretation:

__________________________________________
Clinical Significance:

Group No. ____


Section: ______
Members (indicate if absent)

Exercise Number: 15
Serologic Tests: Dengue Duo Test
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

Component/s fixed/embedded on the Control Line:


__________________________________________
Component/s fixed on the Test Line:
__________________________________________

Interpretation:

__________________________________________
Clinical Significance:
Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 16
Serologic Tests: H. pylori
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

Component/s fixed/embedded on the Control Line:


__________________________________________
Component/s fixed on the Test Line:
__________________________________________

Interpretation:

__________________________________________
Clinical Significance:

Group No. ____


Section: ______
Members (indicate if absent)

Exercise Number: 17
Serologic Tests: HBsAg
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

Component/s fixed/embedded on the Control Line:


__________________________________________
Component/s fixed on the Test Line:
__________________________________________

Interpretation:

__________________________________________
Clinical Significance:
Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 18
Serologic Tests: Malaria Test
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

Component/s fixed/embedded on the Control Line:


__________________________________________
Component/s fixed on the Test Line:
__________________________________________

Interpretation:

__________________________________________
Clinical Significance:

Group No. ____


Section: ______
Members (indicate if absent)

Exercise Number: 18
Serologic Tests: HCV
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

Component/s fixed/embedded on the Control Line:


__________________________________________
Component/s fixed on the Test Line:
__________________________________________

Interpretation:

__________________________________________
Clinical Significance:
Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 18
Serologic Tests: AFP ELISA
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

Component Attached to the Well

Analyte of Interest

Clinical Significance
Group No. ____
Section: ______
Members (indicate if absent)

Exercise Number: 20
Serologic Tests: Syphilis
Objectives:
1.
2.
Observation and Results:
Specimen Code: ________
Serologic Principle: _______________________________

Component/s fixed/embedded on the Control Line:


__________________________________________
Component/s fixed on the Test Line:
__________________________________________

Interpretation:

__________________________________________
Clinical Significance: